. 2021 Oct 27;7(11):e08265. doi: 10.1016/j.heliyon.2021.e08265

Table 2.

Probabilities of remission and recurrence for each drug in base case with sensitivity intervals.

Drugs	Minimum (25%)	Base case probability	Maximum (25%)	Reference
Pyrimethamine sulfadiazine	*Recurrence:* 33.8	*Recurrence:* 45	*Recurrence:* 56.3	[36]
Pyrimethamine sulfadiazine	*Remission:* 41.3	*Remission:* 55	*Remission:* 68.8	[36]
Pyrimethamine sulfadoxine	*Recurrence:* 6.2	*Recurrence:* 8.3	*Recurrence:* 10.4	[37]
Pyrimethamine sulfadoxine	*Remission:* 68.8	*Remission:* 91,7	*Remission:* 114.6	[37]
TMP-SMX	*Recurrence:* 9.8	*Recurrence:* 13	*Recurrence:* 16.3	[29]
TMP-SMX	*Remission:* 65.3	*Remission:* 87	*Remission:* 108.8	[29]
Oral clindamycin^∗	-	-	-	-
Oral clindamycin^∗	-	-	-	-
Dexamethasone with intravitreal clindamycin	*Recurrence:* 9.3	*Recurrence:* 12.5	*Recurrence:* 15.6	[32]
Dexamethasone with intravitreal clindamycin	*Remission:* 65.6	*Remission:* 87.5	*Remission:* 109.4	[32]
Azithromycin	*Recurrence:* 16	*Recurrence:* 21.4	*Recurrence:* 26.8	[38]
Azithromycin	*Remission:* 98.3	*Remission:* 78.6	*Remission:* 58.9	[38]

Abbreviation: TMP-SMX, trimethoprim/sulfamethoxazole.

^∗

To our knowledge, there is no available information regarding remission or recurrence probability with oral clindamycin.